Salomonsson P, Gottberg L, Heilborn H, Norrlind K, Pegelow K O
Dept. of Medicine, University Hospital, Huddinge, Sweden.
Allergy. 1988 Apr;43(3):214-8. doi: 10.1111/j.1398-9995.1988.tb00421.x.
The efficacy and side effects of the oral H1-antihistamine, astemizole, were compared with those of nasal beclomethasone in 158 adult birch-pollen allergic hay fever patients. 148 patients completed the 5-week, controlled trial which took place in Stockholm, May 1986, during the birch pollen season. Daily pollen counts were found to be at a rather low level throughout the study period. The effect and tolerability of both drugs were found to be excellent, although beclomethasone reduced nasal symptoms (sneezing, rhinorrhoea, blocked nose) significantly more effectively than astemizole. Eye symptoms were mild and equal in both groups. The results indicate that oral astemizole is an effective non-sedating antihistamine, though less so than nasal beclomethasone, in the treatment of nasal hay fever symptoms.
在158例成年桦树花粉过敏性花粉症患者中,对比了口服H1抗组胺药阿司咪唑与鼻用倍氯米松的疗效及副作用。148例患者完成了于1986年5月在斯德哥尔摩桦树花粉季节期间进行的为期5周的对照试验。在整个研究期间,每日花粉计数处于相当低的水平。尽管倍氯米松在减轻鼻症状(打喷嚏、流涕、鼻塞)方面比阿司咪唑显著更有效,但发现两种药物的效果和耐受性均良好。眼部症状较轻且两组相同。结果表明,口服阿司咪唑在治疗鼻花粉症症状方面是一种有效的非镇静性抗组胺药,尽管效果不如鼻用倍氯米松。